Catalyst Pharmaceutical Partners, Inc. (NASDAQ: CPRX)

Catalyst Pharmaceutical Partners, Inc. (NASDAQ: CPRX), a specialty pharmaceutical company, is focused on developing and commercializing prescription drugs designed to treat drug addiction. Currently, CPP-109 is being developed to treat addiction to cocaine, methamphetamine and other addictive substances. The company’s mission is much larger than only serving their patients, as they also seek to benefit investors and the society at large. For further information, visit the Company’s web site at www.catalystpharma.com.